Back to Journals » Lung Cancer: Targets and Therapy » Volume 1 » Default

Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer

Authors Wilson C, Danson SJ

Published 13 May 2010 Volume 2010:1 Pages 37—51

DOI https://doi.org/10.2147/LCTT.S9974

Review by Single anonymous peer review

Peer reviewer comments 5



Caroline Wilson, Sarah J Danson

Academic Unit of Clinical Oncology, University of Sheffield, Broomcross Building, Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

Abstract: Lung cancer is the most common cancer worldwide, with 1.3 million new cases diagnosed every year. Non-small-cell lung carcinoma (NSCLC) has previously had a very poor prognosis with few effective therapies; however, research has identified that it is associated with a high rate of expression of epidermal growth factor receptor (EGFR) tyrosine kinase. This has led to discoveries in drug manipulation of this receptor, to provide effective new therapies against NSCLC. Gefitinib is a small molecule kinase inhibitor which inhibits the cytoplasmic domain of the EGFR; the evidence behind its use and future role is presented in this review.

Keywords: non-small-cell lung carcinoma, gefitinib, epidermal growth factor receptor, tyrosine kinase, cigarette smoking

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.